The European Medicines Agency shared on Friday highlights of the latest meeting held by its Pharmacovigilance Risk Assessment Committee, revealing that the committee is investigating cases of thromboembolic events after vaccination using AstraZeneca's COVID-19 vaccine.
"...The vaccine's benefits continue to outweigh its risks and the vaccine can continue to be administered while the investigation of cases of thromboembolic events is ongoing," the statement noted, adding there is still no evidence of direct links between them.
Furthermore, the PRAC recommended an update to the vaccine information to include that allergic reactions such as anaphylaxis and hypersensitivity are happening at an unknown frequency, as well as that confirmed cases of these reactions have already been reported.
